Courtesy of Benzinga.
Analysts at Morgan Stanley initiated coverage on shares of Myriad Genetics (NASDAQ: MYGN) with a Underperform rating.
The target price for Myriad Genetics is set to $25.
Myriad Genetics shares have gained 29.61% over the past 52 weeks, while the S&P 500 index has surged 14.68% in the same period.
Myriad Genetics’ shares fell 1.98% to $34.20 in pre-market trading.
Latest Ratings for MYGN
Date | Firm | Action | From | To |
---|---|---|---|---|
Nov 2014 | Morgan Stanley | Initiates Coverage on | Underperform | |
Aug 2014 | Credit Suisse | Maintains | Neutral | |
Jun 2014 | Macquarie | Maintains | Neutral |
View More Analyst Ratings for MYGN
View the Latest Analyst Ratings
Posted-In: Morgan StanleyInitiation Analyst Ratings